Current Report Filing (8-k)
April 07 2017 - 5:02PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported):
April 5, 2017
ADVAXIS,
INC.
(Exact
Name of Registrant as Specified in Charter)
Delaware
(State
or Other Jurisdiction
of
Incorporation)
|
|
000-28489
(Commission
File
Number)
|
|
02-0563870
(IRS
Employer
Identification
No.)
|
305
College Road East
Princeton,
New Jersey, 08540
(Address
of Principal Executive Offices)
(609)
452-9813
(Registrant’s
telephone number, including area code)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act.
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act.
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2b under the Exchange Act.
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act.
|
Item
5.07. Submission of Matters to a Vote of Security Holders.
The
2017 annual meeting of stockholders of Advaxis was held on April 5, 2017. The following matters were voted on by the stockholders:
the election of directors, the approval of an amendment to Advaxis’ 2015 Incentive Plan to authorize an additional 1,500,000
shares thereunder and to include a provision for pre-defined annual increases in the number of shares available for issuance,
the ratification of 2015 stock option grants under Advaxis’ 2015 Incentive Plan to certain directors and officers, and the
ratification of the appointment of Marcum LLP as Advaxis’ independent registered public accounting firm for the fiscal year
ending October 31, 2017. At the meeting, Dr. David Sidransky, Dr. James P. Patton, Daniel J. O’Connor, Roni A. Appel, Richard
J. Berman, Dr. Samir N. Khleif, Dr. Thomas J. McKearn, and Thomas J. Ridge were re-elected to the Board.
Proposal
1
The
vote with respect to each nominee is set forth below:
Nominee
|
|
Total
Votes For
|
|
|
Total
Votes Withheld
|
|
|
Broker
Non-Votes
|
|
Dr. David
Sidransky
|
|
|
12,324,390
|
|
|
|
6,540,383
|
|
|
|
14,532,686
|
|
Dr. James P. Patton
|
|
|
12,589,076
|
|
|
|
6,275,697
|
|
|
|
14,532,686
|
|
Daniel J. O’Connor
|
|
|
18,263,858
|
|
|
|
600,915
|
|
|
|
14,532,686
|
|
Roni A. Appel
|
|
|
18,358,386
|
|
|
|
506,387
|
|
|
|
14,532,686
|
|
Richard J. Berman
|
|
|
18,339,699
|
|
|
|
525,074
|
|
|
|
14,532,686
|
|
Dr. Samir Khleif
|
|
|
12,761,138
|
|
|
|
6,103,635
|
|
|
|
14,532,686
|
|
Dr. Thomas J. McKearn
|
|
|
12,709,321
|
|
|
|
6,155,452
|
|
|
|
14,532,686
|
|
Thomas J. Ridge
|
|
|
18,378,020
|
|
|
|
486,753
|
|
|
|
14,532,686
|
|
Proposal
2
The
vote with respect to the approval of an amendment to Advaxis’ 2015 Incentive Plan is set forth below:
Total
Votes For
|
|
|
Total
Votes Against
|
|
|
Abstentions
|
|
|
Broker
Non-Votes
|
|
|
10,328,658
|
|
|
|
8,407,892
|
|
|
|
128,223
|
|
|
|
14,532,686
|
|
Proposal
3
The
vote with respect to the ratification of 2015 stock option grants under Advaxis’ 2015 Incentive Plan is set forth below:
Total Votes For
|
|
|
Total Votes Against
|
|
|
Abstentions
|
|
|
Broker Non-Votes
|
|
|
10,644,448
|
|
|
|
8,045,834
|
|
|
|
174,491
|
|
|
|
14,532,686
|
|
Proposal
4
The
vote with respect to the ratification of the appointment of Marcum LLP as Advaxis’ independent registered public accounting
firm for the fiscal year ending October 31, 2017, is set forth below:
Total Votes For
|
|
|
Total Votes Against
|
|
|
Abstentions
|
|
|
32,496,795
|
|
|
|
636,064
|
|
|
|
264,600
|
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
ADVAXIS, INC.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/
Daniel J. O’Connor
|
|
|
Daniel J. O’Connor
|
|
|
President and Chief
Executive Officer
|
Date:
April 7, 2017
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024